Antitumor activity of kinetochore-associated protein 2 siRNA against lung cancer patient-derived tumor xenografts

  • Authors:
    • Yukimasa Makita
    • Mika Teratani
    • Shumpei Murata
    • Yasutaka Hoashi
    • Satoru Matsumoto
    • Yuji Kawamata
  • View Affiliations

  • Published online on: January 29, 2018     https://doi.org/10.3892/ol.2018.7890
  • Pages: 4676-4682
Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

It has been widely reported that patient-derived tumor xenografts (PDXs) are more similar to tumor tissues than conventional cancer cell lines. Kinetochore‑associated protein 2 (KNTC2) is known to be upregulated specifically in tumor tissues of cancer patients and is recognized as a potential target for cancer therapy. Previously, in vivo antitumor activities of KNTC2 short interfering RNA encapsulated into a lipid nanoparticle (KNTC2‑LNP) were reported in orthotopic hepatocellular carcinoma mouse models. However, it remains unclear whether KNTC2‑LNP exhibits antitumor activities against lung cancer PDXs. In the present study, the antitumor activities of KNTC2‑LNP were clarified in a three-dimensional culture system and a subcutaneous tumor model of lung cancer PDX, LC‑60, which was resistant to erlotinib. Growth inhibitory activities of KNTC2‑LNP were associated with knockdown activities. Furthermore, KNTC2‑LNP also exhibited in vivo antitumor activity against another lung cancer PDX, LC‑45, which was sensitive to erlotinib. These results suggest that KNTC2 is a promising target for patients with lung cancer.

References

1 

Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, Arcaroli JJ, Messersmith WA and Eckhardt SG: Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 9:338–350. 2012. View Article : Google Scholar : PubMed/NCBI

2 

Pompili L, Porru M, Caruso C, Biroccio A and Leonetti C: Patient-derived xenografts: A relevant preclinical model for drug development. J Exp Clin Cancer Res. 35:1892016. View Article : Google Scholar : PubMed/NCBI

3 

Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, Becker M and Merk J: Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res. 14:6456–6468. 2008. View Article : Google Scholar : PubMed/NCBI

4 

Wang D, Pham NA, Tong J, Sakashita S, Allo G, Kim L, Yanagawa N, Raghavan V, Wei Y, To C, et al: Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors. Int J Cancer. 140:662–673. 2017. View Article : Google Scholar : PubMed/NCBI

5 

Perez-Soler R, Kemp B, Wu QP, Mao L, Gomez J, Zeleniuch-Jacquotte A, Yee H, Lee JS, Jagirdar J and Ling YH: Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice. Clin Cancer Res. 6:4932–4938. 2000.PubMed/NCBI

6 

Daniel VC, Marchionni L, Hierman JS, Rhodes JT, Devereux WL, Rudin CM, Yung R, Parmigiani G, Dorsch M, Peacock CD and Watkins DN: A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 69:3364–3373. 2009. View Article : Google Scholar : PubMed/NCBI

7 

Zhang XC, Zhang J, Li M, Huang XS, Yang XN, Zhong WZ, Xie L, Zhang L, Zhou M, Gavine P, et al: Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: Useful tools for preclinical studies of targeted therapies. J Transl Med. 11:1682013. View Article : Google Scholar : PubMed/NCBI

8 

Ilie M, Nunes M, Blot L, Hofman V, Long-Mira E, Butori C, Selva E, Merino-Trigo A, Vénissac N, Mouroux J, et al: Setting up a wide panel of patient-derived tumor xenografts of non-small cell lung cancer by improving the preanalytical steps. Cancer Med. 4:201–211. 2015. View Article : Google Scholar : PubMed/NCBI

9 

Owonikoko TK, Zhang G, Kim HS, Stinson RM, Bechara R, Zhang C, Chen Z, Saba NF, Pakkala S, Pillai R, et al: Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer. J Transl Med. 14:1112016. View Article : Google Scholar : PubMed/NCBI

10 

Nukatsuka M, Saito H, Nakagawa F, Tsujimoto H, Sakamoto K, Tsukioka S, Uchida J, Kiniwa M, Kobunai T and Takechi T: Combination therapy using oral S-1 and targeted agents against human tumor xenografts in nude mice. Exp Ther Med. 3:755–762. 2012. View Article : Google Scholar : PubMed/NCBI

11 

Hu Y, Wang L, Gu J, Qu K and Wang Y: Identification of microRNA differentially expressed in three subtypes of non-small cell lung cancer and in silico functional analysis. Oncotarget. 8:74554–74566. 2017.PubMed/NCBI

12 

Nicholson AG, Chansky K, Crowley J, Beyruti R, Kubota K, Turrisi A, Eberhardt WE, van Meerbeeck J and Rami-Porta R; Staging and Prognostic Factors Committee, ; Advisory Boards, and Participating Institutions, ; Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions, : The international association for the study of lung cancer lung cancer staging project: Proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming Eighth edition of the TNM classification for lung cancer. J Thorac Oncol. 11:300–311. 2016. View Article : Google Scholar : PubMed/NCBI

13 

Johnson JR, Cohen M, Sridhara R, Chen YF, Williams GM, Duan J, Gobburu J, Booth B, Benson K, Leighton J, et al: Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res. 11:6414–6421. 2005. View Article : Google Scholar : PubMed/NCBI

14 

Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, et al: First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol. 26:2442–2449. 2008. View Article : Google Scholar : PubMed/NCBI

15 

Dungo RT and Keating GM: Afatinib: First global approval. Drugs. 73:1503–1515. 2013. View Article : Google Scholar : PubMed/NCBI

16 

Malik SM, Maher VE, Bijwaard KE, Becker RL, Zhang L, Tang SW, Song P, Liu Q, Marathe A, Gehrke B, et al: U.S. food and drug administration approval: Crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive. Clin Cancer Res. 20:2029–2034. 2014. View Article : Google Scholar : PubMed/NCBI

17 

Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, et al: Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): Updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol. 17:452–463. 2016. View Article : Google Scholar : PubMed/NCBI

18 

Song Z, Wang M and Zhang A: Alectinib: A novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance. Acta Pharm Sin B. 5:34–37. 2015. View Article : Google Scholar : PubMed/NCBI

19 

Hazarika M, White RM, Johnson JR and Pazdur R: FDA drug approval summaries: Pemetrexed (Alimta). Oncologist. 9:482–488. 2004. View Article : Google Scholar : PubMed/NCBI

20 

Cohen MH, Gootenberg J, Keegan P and Pazdur R: FDA drug approval summary: Bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist. 12:713–718. 2007. View Article : Google Scholar : PubMed/NCBI

21 

Salgia R, Stille JR, Weaver RW, McCleod M, Hamid O, Polzer J, Roberson S, Flynt A and Spigel DR: A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer. Lung Cancer. 105:7–13. 2017. View Article : Google Scholar : PubMed/NCBI

22 

Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al: Nivolumab versus docetaxel in advanced Squamous-cell Non-small-cell lung cancer. N Engl J Med. 373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI

23 

Chen Y, Riley DJ, Chen PL and Lee WH: HEC, a novel nuclear protein rich in leucine heptad repeats specifically involved in mitosis. Mol Cell Biol. 17:6049–6056. 1997. View Article : Google Scholar : PubMed/NCBI

24 

Ferretti C, Totta P, Fiore M, Mattiuzzo M, Schillaci T, Ricordy R, Di Leonardo A and Degrassi F: Expression of the kinetochore protein Hec1 during the cell cycle in normal and cancer cells and its regulation by the pRb pathway. Cell Cycle. 9:4174–4182. 2010. View Article : Google Scholar : PubMed/NCBI

25 

Makita Y, Murata S, Katou Y, Kikuchi K, Uejima H, Teratani M, Hoashi Y, Kenjo E, Matsumoto S, Nogami M, et al: Anti-tumor activity of KNTC2 siRNA in orthotopic tumor model mice of hepatocellular carcinoma. Biochem Biophys Res Commun. 493:800–806. 2017. View Article : Google Scholar : PubMed/NCBI

26 

Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K and Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 411:494–498. 2001. View Article : Google Scholar : PubMed/NCBI

27 

Frank-Kamenetsky M, Grefhorst A, Anderson NN, Racie TS, Bramlage B, Akinc A, Butler D, Charisse K, Dorkin R, Fan Y, et al: Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci USA. 105:pp. 11915–11920. 2008; View Article : Google Scholar : PubMed/NCBI

28 

Hoashi Y: Cationic Lipid Patent WO2016021683 A1. August 6–2015, issued February 11, 2016.

29 

Heyes J, Palmer L, Bremner K and MacLachlan I: Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J Control Release. 107:276–287. 2005. View Article : Google Scholar : PubMed/NCBI

30 

Sato T, Stange DE, Ferrante M, Vries RG, Van Es JH, Van den Brink S, Van Houdt WJ, Pronk A, Van Gorp J, Siersema PD and Clevers H: Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology. 141:1762–1772. 2011. View Article : Google Scholar : PubMed/NCBI

31 

Schneeberger VE, Allaj V, Gardner EE, Poirier JT and Rudin CM: Quantitation of murine stroma and selective purification of the human tumor component of patient-derived xenografts for genomic analysis. PLoS One. 11:e01605872016. View Article : Google Scholar : PubMed/NCBI

32 

Taromi S, Kayser G, Catusse J, von Elverfeldt D, Reichardt W, Braun F, Weber WA, Zeiser R and Burger M: CXCR4 antagonists suppress small cell lung cancer progression. Oncotarget. 7:85185–85195. 2016. View Article : Google Scholar : PubMed/NCBI

33 

Wu G, Qiu XL, Zhou L, Zhu J, Chamberlin R, Lau J, Chen PL and Lee WH: Small molecule targeting the Hec1/Nek2 mitotic pathway suppresses tumor cell growth in culture and in animal. Cancer Res. 68:8393–8399. 2008. View Article : Google Scholar : PubMed/NCBI

34 

Hu CM, Zhu J, Guo XE, Chen W, Qiu XL, Ngo B, Chien R, Wang YV, Tsai CY, Wu G, et al: Novel small molecules disrupting Hec1/Nek2 interaction ablate tumor progression by triggering Nek2 degradation through a death-trap mechanism. Oncogene. 34:1220–1230. 2015. View Article : Google Scholar : PubMed/NCBI

35 

Pollack VA, Savage DM, Baker DA, Tsaparikos KE, Sloan DE, Moyer JD, Barbacci EG, Pustilnik LR, Smolarek TA, Davis JA, et al: Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther. 291:739–748. 1999.PubMed/NCBI

36 

Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG and Varmus HE: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2:e172005. View Article : Google Scholar : PubMed/NCBI

37 

Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG and Varmus H: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2:e732005. View Article : Google Scholar : PubMed/NCBI

38 

Ekert JE, Johnson K, Strake B, Pardinas J, Jarantow S, Perkinson R and Colter DC: Three-dimensional lung tumor microenvironment modulates therapeutic compound responsiveness in vitro-implication for drug development. PLoS One. 9:e922482014. View Article : Google Scholar : PubMed/NCBI

39 

Friedrich J, Seidel C, Ebner R and Kunz-Schughart LA: Spheroid-based drug screen: Considerations and practical approach. Nat Protoc. 4:309–324. 2009. View Article : Google Scholar : PubMed/NCBI

40 

Perche F and Torchilin VP: Cancer cell spheroids as a model to evaluate chemotherapy protocols. Cancer Biol Ther. 13:1205–1213. 2012. View Article : Google Scholar : PubMed/NCBI

41 

Endo H, Okami J, Okuyama H, Kumagai T, Uchida J, Kondo J, Takehara T, Nishizawa Y, Imamura F, Higashiyama M and Inoue M: Spheroid culture of primary lung cancer cells with neuregulin 1/HER3 pathway activation. J Thorac Oncol. 8:131–139. 2013. View Article : Google Scholar : PubMed/NCBI

42 

Onion D, Argent RH, Reece-Smith AM, Craze ML, Pineda RG, Clarke PA, Ratan HL, Parsons SL, Lobo DN, Duffy JP, et al: 3-Dimensional patient-derived lung cancer assays reveal resistance to Standards-of-Care promoted by stromal cells but sensitivity to histone deacetylase inhibitors. Mol Cancer Ther. 15:753–763. 2016. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

April 2018
Volume 15 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Makita, Y., Teratani, M., Murata, S., Hoashi, Y., Matsumoto, S., & Kawamata, Y. (2018). Antitumor activity of kinetochore-associated protein 2 siRNA against lung cancer patient-derived tumor xenografts. Oncology Letters, 15, 4676-4682. https://doi.org/10.3892/ol.2018.7890
MLA
Makita, Y., Teratani, M., Murata, S., Hoashi, Y., Matsumoto, S., Kawamata, Y."Antitumor activity of kinetochore-associated protein 2 siRNA against lung cancer patient-derived tumor xenografts". Oncology Letters 15.4 (2018): 4676-4682.
Chicago
Makita, Y., Teratani, M., Murata, S., Hoashi, Y., Matsumoto, S., Kawamata, Y."Antitumor activity of kinetochore-associated protein 2 siRNA against lung cancer patient-derived tumor xenografts". Oncology Letters 15, no. 4 (2018): 4676-4682. https://doi.org/10.3892/ol.2018.7890